10x Genomics Stock Performance
| TXG Stock | USD 10.29 0.22 2.09% |
The firm shows a Beta (market volatility) of 1.44, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, 10X Genomics will likely underperform. At this point, 10X Genomics has a negative expected return of -0.43%. Please make sure to confirm 10X Genomics' total risk alpha, as well as the relationship between the skewness and day median price , to decide if 10X Genomics performance from the past will be repeated sooner or later.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days 10X Genomics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite uncertain performance in the last few months, the Stock's basic indicators remain nearly stable which may send shares a bit higher in April 2025. The current disturbance may also be a sign of long-run up-swing for the company stockholders. ...more
Actual Historical Performance (%)
One Day Return (2.09) | Five Day Return 2.29 | Year To Date Return (27.48) | Ten Year Return (80.49) | All Time Return (80.49) |
Last Split Factor 1:2 | Last Split Date 2006-07-17 |
1 | 10x Genomics Cash Flow from Financing 11.1 Mil - GuruFocus.com | 01/16/2025 |
2 | Disposition of 4660 shares by Serge Saxonov of 10X Genomics at 43.9959 subject to Rule 16b-3 | 01/31/2025 |
3 | Insider Trading | 02/07/2025 |
4 | 10x Genomics Inc Trading Down 15.3 percent on Feb 10 | 02/10/2025 |
5 | Q4 2024 10X Genomics Inc Earnings Call Transcript | 02/13/2025 |
6 | 10x Genomics Downgraded by Leerink Partnrs to Hold | 02/14/2025 |
7 | 10x Genomics to Participate in the 45th Annual TD Cowen Health Care Conference | 02/18/2025 |
8 | 10x Genomics, Inc. Receives Consensus Recommendation of Hold from Analysts | 02/26/2025 |
9 | Disposition of 7942 shares by Serge Saxonov of 10X Genomics at 10.6262 subject to Rule 16b-3 | 02/28/2025 |
10 | 10x Genomics Inc Stock Price Down 3.41 percent on Mar 3 | 03/03/2025 |
11 | Disposition of 50000 shares by Serge Saxonov of 10X Genomics at 1.2 subject to Rule 16b-3 | 03/04/2025 |
12 | Disposition of 1700 shares by Serge Saxonov of 10X Genomics at 55.1465 subject to Rule 16b-3 | 03/07/2025 |
13 | 2 Reasons to Sell TXG and 1 Stock to Buy Instead | 03/11/2025 |
| Begin Period Cash Flow | 359.3 M |
10X |
10X Genomics Relative Risk vs. Return Landscape
If you would invest 1,404 in 10X Genomics on December 20, 2024 and sell it today you would lose (375.00) from holding 10X Genomics or give up 26.71% of portfolio value over 90 days. 10X Genomics is generating negative expected returns assuming volatility of 4.3158% on return distribution over 90 days investment horizon. In other words, 38% of stocks are less volatile than 10X, and above 99% of all equities are expected to generate higher returns over the next 90 days. Expected Return |
| Risk |
10X Genomics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for 10X Genomics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as 10X Genomics, and traders can use it to determine the average amount a 10X Genomics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0999
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | TXG |
Estimated Market Risk
| 4.32 actual daily | 38 62% of assets are more volatile |
Expected Return
| -0.43 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.1 actual daily | 0 Most of other assets perform better |
Based on monthly moving average 10X Genomics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of 10X Genomics by adding 10X Genomics to a well-diversified portfolio.
10X Genomics Fundamentals Growth
10X Stock prices reflect investors' perceptions of the future prospects and financial health of 10X Genomics, and 10X Genomics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on 10X Stock performance.
| Return On Equity | -0.25 | ||||
| Return On Asset | -0.13 | ||||
| Profit Margin | (0.30) % | ||||
| Operating Margin | (0.30) % | ||||
| Current Valuation | 1.01 B | ||||
| Shares Outstanding | 108.25 M | ||||
| Price To Book | 1.85 X | ||||
| Price To Sales | 2.15 X | ||||
| Revenue | 610.78 M | ||||
| Gross Profit | 414.78 M | ||||
| EBITDA | (133.99 M) | ||||
| Net Income | (182.63 M) | ||||
| Cash And Equivalents | 499.73 M | ||||
| Cash Per Share | 4.39 X | ||||
| Total Debt | 82.61 M | ||||
| Debt To Equity | 0.13 % | ||||
| Current Ratio | 5.65 X | ||||
| Book Value Per Share | 5.81 X | ||||
| Cash Flow From Operations | 6.66 M | ||||
| Earnings Per Share | (1.52) X | ||||
| Market Capitalization | 1.32 B | ||||
| Total Asset | 918.64 M | ||||
| Retained Earnings | (1.47 B) | ||||
| Working Capital | 466.75 M | ||||
About 10X Genomics Performance
By analyzing 10X Genomics' fundamental ratios, stakeholders can gain valuable insights into 10X Genomics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if 10X Genomics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if 10X Genomics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 154.53 | 138.06 | |
| Return On Tangible Assets | (0.20) | (0.21) | |
| Return On Capital Employed | (0.24) | (0.26) | |
| Return On Assets | (0.20) | (0.21) | |
| Return On Equity | (0.26) | (0.27) |
Things to note about 10X Genomics performance evaluation
Checking the ongoing alerts about 10X Genomics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for 10X Genomics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| 10X Genomics generated a negative expected return over the last 90 days | |
| 10X Genomics has high historical volatility and very poor performance | |
| The company reported the last year's revenue of 610.78 M. Reported Net Loss for the year was (182.63 M) with profit before taxes, overhead, and interest of 414.78 M. | |
| Over 97.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: 2 Reasons to Sell TXG and 1 Stock to Buy Instead |
- Analyzing 10X Genomics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether 10X Genomics' stock is overvalued or undervalued compared to its peers.
- Examining 10X Genomics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating 10X Genomics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of 10X Genomics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of 10X Genomics' stock. These opinions can provide insight into 10X Genomics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for 10X Stock analysis
When running 10X Genomics' price analysis, check to measure 10X Genomics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy 10X Genomics is operating at the current time. Most of 10X Genomics' value examination focuses on studying past and present price action to predict the probability of 10X Genomics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move 10X Genomics' price. Additionally, you may evaluate how the addition of 10X Genomics to your portfolios can decrease your overall portfolio volatility.
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios |